Dyadic International IncNASDAQ:DYAI
- LAST PRICE1.0500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8861/ 1
- Ask / Lots1.1500/ 1
- Open / Previous Close--- / 1.0500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DYAI |
|---|---|---|
| 09:32 ET | 454 | 1.11 |
| 09:46 ET | 100 | 1.14 |
| 10:13 ET | 500 | 1.1001 |
| 10:18 ET | 4882 | 1.05 |
| 10:27 ET | 150 | 1.12 |
| 10:33 ET | 490 | 1.1 |
| 12:19 ET | 3100 | 1.08 |
| 12:21 ET | 2600 | 1.0886 |
| 12:32 ET | 500 | 1.08 |
| 12:44 ET | 300 | 1.0999 |
| 02:43 ET | 4300 | 1.0996 |
| 03:50 ET | 5150 | 1.07 |
| 03:55 ET | 580 | 1.066 |
| 03:57 ET | 100 | 1.05 |
| 04:00 ET | 1598 | 1.05 |
Nov 4, 2024
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024, from 4:30PM ET on Monday Nov 04, 2024 by Dow Jones
4:30PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dyadic International Inc | 31.0M | -3.9x | --- |
Lipocine Inc | 28.5M | -3.3x | --- |
Marker Therapeutics Inc | 33.8M | -3.3x | --- |
SAB Biotherapeutics Inc | 29.4M | -0.6x | --- |
IGC Pharma Inc | 28.7M | -1.8x | --- |
Lumos Pharma Inc | 37.8M | -1.0x | --- |
Company Information
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Contact Information
- Headquarters
- 1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER, FL, United States 33477
- Phone
- 561-743-8333
- Fax
- 561-743-8343
Executives
- Independent Chairman of the Board
- Patrick Lucy
- President, Chief Executive Officer, Director
- Mark Emalfarb
- Chief Financial Officer
- Ping Rawson
- Chief Operating Officer
- Joseph Hazelton
- Vice President of Research and Business Development
- Ronen Tchelet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.0M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 29.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-0.27 |
Book Value | $0.20 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 17.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -443.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
